Volume 61, Issue 4, Pages (April 2012)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Volume 165, Issue 5, Pages (May 2001)

Volume 65, Issue 6, Pages (June 2014)

Volume 58, Issue 2, Pages (August 2010)

Volume 55, Issue 3, Pages (March 2009)

European Urology Focus

Volume 66, Issue 6, Pages (December 2014)

Volume 58, Issue 1, Pages (July 2010)

Volume 60, Issue 2, Pages (August 2011)

Volume 67, Issue 4, Pages (April 2015)

Volume 52, Issue 1, Pages (July 2007)

Volume 57, Issue 6, Pages (June 2010)

European Urology Oncology

Volume 49, Issue 2, Pages (February 2006)

Volume 66, Issue 1, Pages (July 2014)

Volume 61, Issue 5, Pages (May 2012)

Volume 63, Issue 4, Pages (April 2013)

Volume 68, Issue 3, Pages (September 2015)

Volume 52, Issue 3, Pages (September 2007)

Volume 51, Issue 3, Pages (March 2007)

Volume 65, Issue 6, Pages (June 2014)

The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy Olaf A. Brinkmann,

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Volume 72, Issue 5, Pages (November 2017)

Volume 52, Issue 4, Pages (October 2007)

Volume 63, Issue 4, Pages (April 2013)

Volume 67, Issue 4, Pages (April 2015)

Volume 63, Issue 1, Pages (January 2013)

Volume 66, Issue 2, Pages (August 2014)

Nomograms for Bladder Cancer

Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 55, Issue 6, Pages (June 2009)

Volume 73, Issue 2, Pages (February 2018)

Volume 61, Issue 5, Pages (May 2012)

Volume 61, Issue 4, Pages (April 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 5, Pages (November 2016)

Volume 67, Issue 3, Pages (March 2015)

Volume 64, Issue 5, Pages (November 2013)

Volume 55, Issue 3, Pages (March 2009)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 4, Pages (October 2013)

Volume 66, Issue 6, Pages (December 2014)

Volume 66, Issue 6, Pages (December 2014)

Mark A. Rubin, Gabriele Girelli, Francesca Demichelis European Urology

Volume 67, Issue 6, Pages (June 2015)

Volume 62, Issue 2, Pages (August 2012)

Volume 56, Issue 5, Pages (November 2009)

Volume 47, Issue 1, Pages (January 2005)

Volume 53, Issue 1, Pages (January 2008)

Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.

Volume 71, Issue 6, Pages (June 2017)

Volume 71, Issue 5, Pages (May 2017)

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Volume 145, Issue 2, Pages (May 2017)

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

European Urology Oncology

Molecular prognostication of liver cancer: End of the beginning

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Erratum Journal of Thoracic Oncology

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Volume 54, Issue 1, Pages (July 2008)

Georges-Pascal Haber, Sebastien Crouzet, Inderbir S. Gill

Volume 52, Issue 4, Pages (October 2007)

Volume 52, Issue 1, Pages (July 2007)

Volume 54, Issue 1, Pages (July 2008)

Presentation transcript:

Volume 61, Issue 4, Pages 810-817 (April 2012) Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study Michael Rink, Felix K. Chun, Roland Dahlem, Armin Soave, Sarah Minner, Jens Hansen, Malgorzata Stoupiec, Cornelia Coith, Luis A. Kluth, Sascha A. Ahyai, Martin G. Friedrich, Shahrokh F. Shariat, Margit Fisch, Klaus Pantel, Sabine Riethdorf European Urology Volume 61, Issue 4, Pages 810-817 (April 2012) DOI: 10.1016/j.eururo.2012.01.017 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier plots of (A) recurrence-free, (B) cancer-specific, and (C) overall survival stratified according to circulating tumor cells (CTC) status (positive vs negative) in 100 patients treated with radical cystectomy and bilateral lymphadenectomy for urothelial carcinoma of the bladder. SD=standard deviation. European Urology 2012 61, 810-817DOI: (10.1016/j.eururo.2012.01.017) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier plots of (A) recurrence-free, (B) cancer-specific, and (C) overall survival stratified according to numbers of circulating tumor cells (CTC; 1 CTC vs ≥2 CTC/7.5ml) in 23 CTC-positive patients treated with radical cystectomy and bilateral lymphadenectomy for urothelial carcinoma of the bladder. European Urology 2012 61, 810-817DOI: (10.1016/j.eururo.2012.01.017) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Determination of human epidermal growth factor receptor 2 (HER2) status by (A) fluorescent in situ hybridization and (B) immunofluorescence using the CellSearch system. (A) Primary tumor with strong HER2 gene amplification (clusters of HER2 signals: red; CEP17 signals: green); (B) circulating tumor cells detected with the CellSearch system (0: HER2 negative; 1+: weak; 2+: moderate; 3+: strong intensity of HER2-specific immunofluorescence). European Urology 2012 61, 810-817DOI: (10.1016/j.eururo.2012.01.017) Copyright © 2012 European Association of Urology Terms and Conditions